Chanelle Group named Exporter of the Year 2016

The Chanelle team celebrates at the Irish Exporters Awards.

The Chanelle team celebrates at the Irish Exporters Awards.

There was good news for Loughrea-based Chanelle Group at the The Export Industry Awards 2016 held last week. The ceremony is the premier event recognising the remarkable achievements of companies working in the export industry in Ireland. 11 companies won individual category Awards across a range of sectors.

The Chanelle Group took home the overall Exporter of the Year Award 2016 after winning both the Life Sciences Exporter of the Year and Export Innovation of the Year award categories earlier in the evening. Over 500 export industry professionals attended the black tie Awards Ceremony and Gala Dinner which took place at the Convention Centre, Dublin.

The Chanelle Group provides a spectrum of services in areas of research and development, and registration and production of generic pharmaceuticals for both human and veterinary pharmaceuticals. Headquartered in Loughrea, the company was founded in 1983 by Michael Burke, a veterinary surgeon.

Chanelle Group currently employs 385 people, over 300 of whom are based at its headquarters in Loughrea. The company plays a pivotal role in employment in the area and exports to over 80 countries worldwide, with key markets in the EU, Australia, New Zealand, Japan, South Africa and the Middle East.

Speaking at the Awards Ceremony, Paschal McCarthy, President of the Irish Exporters Association said: “The Irish Exporters Association Annual Awards is a ceremony to honour the many achievements of the export sector and the companies that support it. It highlights the range of exporting companies driving our economy which enable us to compete globally.

“We are delighted to announce The Chanelle Group as the winner of the Overall Exporter of the Year 2016. This year has been the most competitive yet in the standard of award entrants but our judges were struck by The Chanelle Group’s pioneering approach to product innovation, in particular, the development of super generics, a key factor in the company’s substantial growth in recent years.

“Over the past 12 months Chanelle has catapulted to become a key player in the pharmaceutical industry. The company has surpassed industry norms in areas of product development and commercialisation and they have ambitious growth plans. We wish The Chanelle Group every success in the years to come,” he concluded.

Advertisement

 

Page generated in 0.1952 seconds.